Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262117510> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2262117510 abstract "Introduction: Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors block platelet aggregation following fibrinolysis. No phase III randomized clinical trial has assessed efficacy of combination therapy [Gp IIb/IIIa + IV tissue plasminogen activator (tPA)] to standard of care in acute ischemic stroke. Aim: To conduct a retrospective pooled analysis of data from published prospective studies and randomized phase 1 and 2 trials, to assess efficacy and safety profile of IV combination therapy (Gp IIb/IIIa inhibitors and tPA) in management of acute ischemic stroke. Methods: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed and EMBASE databases, and 3 reviewers independently selected studies reporting safety endpoints and outcome measures in acute ischemic stroke patients treated with low dose tPA + eptifibatide. Demographic/ clinical variables: sex, age, NIH stroke scale (NIHSS) at presentation and Time-to-treatment, Safety endpoint: symptomatic intracranial hemorrhage (sICH), as well as outcome measures: Death at 90 days and modified Rankin score (mRS) 0-1 were consolidated into the two groups. tPA arm of the NINDS tPA trial was included in the tPA only group. Weighted means and proportions were calculated for numeric and categorical variables respectively. Bivariate analysis to compare baseline descriptors, safety endpoints and outcome measures consisted of Fisher’s exact test. Results: 188 patients comprised the combination therapy arm, whereas the IV tPA arm had 218 patients. Mean NIHSS in the two groups were 12.8 and 14.6 respectively. Mean time-to-treatment was 2.3 hours in combination therapy arm and 2.55 hours in the tPA arm. Treatment with combination therapy was associated with a better functional outcome (mRS 0-1) (OR 1.79, 95% CI 1.15 - 2.80, p <0.01) at 90 days. There was also a significant reduction in the rate of sICH (OR 0.26, 95% CI 0.07 - 0.83) in the combination therapy group. Death at 90 days was not significantly different in the 2 groups (OR 1.26, 95% CI 0.73 - 2.18). Conclusion: Combination of low dose IV tPA with Gp IIb/IIIa inhibitor is associated with a better functional outcome at 90 days, as well as a reduction in sICH rates in patients with acute ischemic stroke, as compared to 0.9g/kg IV tPA." @default.
- W2262117510 created "2016-06-24" @default.
- W2262117510 creator A5058838631 @default.
- W2262117510 creator A5070623500 @default.
- W2262117510 creator A5073062736 @default.
- W2262117510 date "2014-02-01" @default.
- W2262117510 modified "2023-09-24" @default.
- W2262117510 title "Abstract T MP81: Combination Therapy of Intravenous Glycoprotein IIb-IIIa Inhibitors and Low Dose Tissue Plasminogen Activator for Acute Ischemic Stroke" @default.
- W2262117510 doi "https://doi.org/10.1161/str.45.suppl_1.tmp81" @default.
- W2262117510 hasPublicationYear "2014" @default.
- W2262117510 type Work @default.
- W2262117510 sameAs 2262117510 @default.
- W2262117510 citedByCount "0" @default.
- W2262117510 crossrefType "journal-article" @default.
- W2262117510 hasAuthorship W2262117510A5058838631 @default.
- W2262117510 hasAuthorship W2262117510A5070623500 @default.
- W2262117510 hasAuthorship W2262117510A5073062736 @default.
- W2262117510 hasConcept C126322002 @default.
- W2262117510 hasConcept C127413603 @default.
- W2262117510 hasConcept C141071460 @default.
- W2262117510 hasConcept C168563851 @default.
- W2262117510 hasConcept C203092338 @default.
- W2262117510 hasConcept C2776572282 @default.
- W2262117510 hasConcept C2780645631 @default.
- W2262117510 hasConcept C2780931571 @default.
- W2262117510 hasConcept C2781056559 @default.
- W2262117510 hasConcept C2909817843 @default.
- W2262117510 hasConcept C3020199598 @default.
- W2262117510 hasConcept C45393284 @default.
- W2262117510 hasConcept C500558357 @default.
- W2262117510 hasConcept C541997718 @default.
- W2262117510 hasConcept C71924100 @default.
- W2262117510 hasConcept C78519656 @default.
- W2262117510 hasConceptScore W2262117510C126322002 @default.
- W2262117510 hasConceptScore W2262117510C127413603 @default.
- W2262117510 hasConceptScore W2262117510C141071460 @default.
- W2262117510 hasConceptScore W2262117510C168563851 @default.
- W2262117510 hasConceptScore W2262117510C203092338 @default.
- W2262117510 hasConceptScore W2262117510C2776572282 @default.
- W2262117510 hasConceptScore W2262117510C2780645631 @default.
- W2262117510 hasConceptScore W2262117510C2780931571 @default.
- W2262117510 hasConceptScore W2262117510C2781056559 @default.
- W2262117510 hasConceptScore W2262117510C2909817843 @default.
- W2262117510 hasConceptScore W2262117510C3020199598 @default.
- W2262117510 hasConceptScore W2262117510C45393284 @default.
- W2262117510 hasConceptScore W2262117510C500558357 @default.
- W2262117510 hasConceptScore W2262117510C541997718 @default.
- W2262117510 hasConceptScore W2262117510C71924100 @default.
- W2262117510 hasConceptScore W2262117510C78519656 @default.
- W2262117510 hasIssue "suppl_1" @default.
- W2262117510 hasLocation W22621175101 @default.
- W2262117510 hasOpenAccess W2262117510 @default.
- W2262117510 hasPrimaryLocation W22621175101 @default.
- W2262117510 hasRelatedWork W1594197285 @default.
- W2262117510 hasRelatedWork W1922527807 @default.
- W2262117510 hasRelatedWork W1965645984 @default.
- W2262117510 hasRelatedWork W1968271050 @default.
- W2262117510 hasRelatedWork W1974108196 @default.
- W2262117510 hasRelatedWork W1996505262 @default.
- W2262117510 hasRelatedWork W1998589931 @default.
- W2262117510 hasRelatedWork W2006909424 @default.
- W2262117510 hasRelatedWork W2010936821 @default.
- W2262117510 hasRelatedWork W2026393945 @default.
- W2262117510 hasRelatedWork W2059215195 @default.
- W2262117510 hasRelatedWork W2074013732 @default.
- W2262117510 hasRelatedWork W2087508766 @default.
- W2262117510 hasRelatedWork W2140313752 @default.
- W2262117510 hasRelatedWork W2157441293 @default.
- W2262117510 hasRelatedWork W2207050574 @default.
- W2262117510 hasRelatedWork W2238882804 @default.
- W2262117510 hasRelatedWork W2400061215 @default.
- W2262117510 hasRelatedWork W2413635536 @default.
- W2262117510 hasRelatedWork W2463248991 @default.
- W2262117510 hasVolume "45" @default.
- W2262117510 isParatext "false" @default.
- W2262117510 isRetracted "false" @default.
- W2262117510 magId "2262117510" @default.
- W2262117510 workType "article" @default.